Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fms-related receptor tyrosine kinase 3 ligand (FLT3LG)
- Target
- FLT3LG
- Molecular classification
- Cytokine (four-helical bundle cytokine), Growth factor, Ligand (for class III receptor tyrosine kinase)
01
Overview
Fms-related receptor tyrosine kinase 3 ligand is a secreted protein belonging to the family of four-helical bundle cytokines and acts as the high-affinity ligand for the FLT3 (CD135) receptor, a class III receptor tyrosine kinase. FLT3LG is essential for the development and homeostasis of dendritic cells and early hematopoietic progenitors; it increases immune cell numbers (including lymphocytes and dendritic cells) primarily by supporting proliferation and differentiation of bone marrow stem cells and their progeny. It is structurally related to stem cell factor and colony-stimulating factor 1 and functions synergistically with other hematopoietic cytokines. Lack of FLT3LG results in a marked deficit in dendritic cells, and dysregulation of the FLT3–FLT3LG axis is implicated in hematopoietic malignancies and immune disorders. The physiological and evolutionary significance of FLT3LG is reinforced by its conservation and key role in vertebrate immunity.
- Other names
- Flt3 ligandFlt3LFLFLT3LFLG3LSL cytokineIMD125FLT3 ligandfms related tyrosine kinase 3 ligand
02
Mechanism of action
For the ligand itself, mechanism of action is by binding to and activating the FLT3 receptor (CD135) on hematopoietic progenitor cells, leading to downstream signaling that supports cell differentiation, survival, and proliferation
03
Biological functions
Regulation of hematopoiesis (blood cell formation)Stimulation of dendritic cell and lymphocyte (B and T cell) developmentImmune response modulationMobilization of hematopoietic progenitor cells
04
Disease associations
Cancer (particularly hematologic cancers)Immunodeficiency (e.g., Immunodeficiency 125)Other immune system disorders
05
Safety considerations
Therapeutic modulation could lead to immune dysregulation, including immunodeficiency, abnormal hematopoiesis, or excessive proliferation of leukocytes (theoretical concerns based on physiological role)
06
Interacting drugs
No well-established direct therapeutic drugs targeting FLT3LG; most therapeutic interventions in this pathway target the FLT3 receptor itself (such as midostaurin, gilteritinib, quizartinib, especially in acute myeloid leukemia)
07
Biomarkers
Dendritic cell and progenitor counts (for immune and hematopoietic system assessment)Implication as a biomarker in immune cell recovery and hematopoietic transplantationLow levels may indicate defects in dendritic cell development
Beyond the preview
Go deeper on Fms-related receptor tyrosine kinase 3 ligand (FLT3LG).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fms-related receptor tyrosine kinase 3 ligand (FLT3LG).